Biogen Inc. buy Royal Bank of Canada
Start price
12.02.24
/
50%
€226.20
Target price
12.02.25
€351.83
Performance (%)
-43.30%
End price
13.02.25
€128.25
Summary
This prediction ended on 13.02.25 with a price of €128.25. The BUY prediction by Royal_Bank_of_Canada for Biogen Inc. performed very badly with a performance of -43.30%. Royal_Bank_of_Canada has a follow-up prediction for Biogen Inc. where he still thinks Biogen Inc. is a Buy. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Biogen Inc. | 0.668% | 0.668% | 52.523% |
| iShares Core DAX® | -0,05 % | 5,96 % | 7,40 % |
| iShares Nasdaq 100 | 0,92 % | 3,69 % | 28,14 % |
| iShares Nikkei 225® | 3,01 % | 6,64 % | 48,89 % |
| iShares S&P 500 | -0,36 % | 2,75 % | 22,53 % |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biogen Inc. diskutieren
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Royal Bank of Canada from $363.00 to $379.00. They now have an "overweight" rating on the stock.
Ratings data for BIIB provided by MarketBeat
In the thread Trading Biogen Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten